Posted by Michael Wonder on 27 Jan 2022
The price of cystic fibrosis drugs is still too high
27 January 2022 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has decided that Kaftrio and Kalydeco for cystic fibrosis will not be subsidised because the price the company is asking for is far above what is reasonable.
This is the second time the company has applied for a subsidy for both medicines.
